ADCY5 and cancer: Finally, and potentially most interesting, we found that the antiviral drug, Vidarabine, previously used in this country and still used in others for Herpes treatment in patients (De Clercq, 1993), has selective AC5 inhibitory properties (Iwatsubo et al., 2012), and that this drug mimics the salutary effects of AC5 disruption on protection against cancer.